| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Monday, July 2, 2018 When Mylan recently announced 500 layoffs at its plant in West Virginia, it said the cuts were “consistent to discussions it was having with the FDA.” What it didn’t say was those discussions included problems the FDA uncovered during a five-week-long inspection of the massive plant. |
|
|
| This week's sponsor is Systech. | |  | [Webinar] Navigating the Path to Compliance: Two Pharmas Discuss Their Challenges and Successes
July 12, 2018 | 11am ET / 8am PT
You know you need to serialize to comply with government mandates such as DSCSA or EU FMD. But the journey from initially Googling "traceability" to achieving full serialization compliance is complex. Let us guide you through the challenges and outcomes with two pharmaceutical companies who have successfully navigated the path to compliance for their different businesses. Register Now. |
Top Stories Of The Week Tuesday, July 3, 2018 Novartis has walked away from Aveo Pharmaceuticals’ AV-380 three years after paying $15 million (€13 million) upfront for the asset. The action cuts short a relationship that was starting to sour amid the slow progress of the treatment for severe, cancer-related weight loss. Thursday, July 5, 2018 Gilead Sciences is eagerly awaiting phase 3 data for its rheumatoid arthritis drug filgotinib due in the next few weeks that could be an antidote for the biotech’s hepatitis C hangover. Monday, July 2, 2018 President Trump may think top drugmakers are ready to step up with price cuts, but Pfizer, for one, is going the other way instead. The pharma giant hiked prices on 100 drugs, including one of its biggest sellers, as of July 1, the Financial Times reports. Tuesday, July 3, 2018 Amgen and Novartis’ Aimovig, first in its new class of migraine drugs, hit the scene in May. And patients were ready for it: so much so that its makers are now overwhelmed in trying to meet initial interest, according to one analyst. Monday, July 2, 2018 The drug metformin has been used to control blood sugar in many patients with Type 2 diabetes for more than two decades. Now scientists at the University of Alabama, Birmingham, have amassed evidence that the drug’s ability to target cell metabolism could help repair the lung. Friday, June 29, 2018 Just eight days after posting a trial win over Merck diabetes stalwart Januvia, Novo Nordisk candidate semaglutide is back with another. Friday, June 29, 2018 Shares of Neuronetics have begun trading on the Nasdaq following a $93.5 million IPO this week, which priced 5.5 million shares of common stock at $17 each, under the ticker symbol STIM. As of Friday morning, shares were up 63% to $27.78. Monday, July 2, 2018 The German dermatology CRO Proinnovera has opened a new U.S. base of operations through a wholly owned subsidiary based in Wilmington, North Carolina. Tuesday, July 3, 2018 Inovio and GeneOne Life Science’s MERS vaccine, which is receiving financial support from the International Vaccine Institute and the Coalition for Epidemic Preparedness Innovations, elicited high levels of antibodies and T-cell responses in a phase 1 study. Enrollment Showcase | | | Sponsored by: Bioinformatics at UTHealth SBMI UTHealth SBMI now offers a M.S. track in clinical and translational bioinformatics. |
|
|
Resources Life Science Strategy Group Take this anonymous 10-minute survey to share your thoughts on leading eClinical technology solutions and earn up to $55 honoraria. Take the survey now! Sponsored by: Blue Latitude Health Blue Latitude Health explores the commercial barriers and new stakeholder connections for pharma companies developing precision medicines, and reveals how to grasp novel opportunities in the new era of healthcare. Presented by: Patheon, part of Thermo Fisher Scientific “Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure. Sponsored by: DocuSign Life science companies are experiencing a significant transformation in how they bring new products to market. |
|
